Methods of using substituted tetracycline compounds to modulate RNA
View Patent ↗A method for modulating RNA with tetracycline compounds is described.
1. A solid pharmaceutical composition comprising a compound of the following formula, or a pharmaceutically acceptable salt, ester, or enantiomer thereof:
wherein:
R 7 is halogen or hydrogen;
R 9 is —NHC(═O)CH 2 R 9a ; and,
R 9a is acyl or heterocyclic; and,
wherein the compound is present in an amount effective to treat Gram-positive and/or Gram-negative bacterial infection with a MIC (minimal inhibition concentration) of less than about 0.5 μg/mL.
2. The compound of claim 1 , wherein R 9a is heterocyclic.
3. The compound of claim 2 , wherein the halogen is fluorine.
4. A pharmaceutical composition comprising the compound of claim 1 or the pharmaceutically acceptable salt, ester, or enantiomer thereof, and a pharmaceutically acceptable carrier.
5. The pharmaceutical composition of claim 4 , wherein R 9a is heterocyclic.
6. The pharmaceutical composition of claim 4 , wherein the halogen is fluorine.
7. The pharmaceutical composition of claim 6 , which is suitable for oral administration.
8. The pharmaceutical composition of claim 6 , which is suitable for parenteral administration.
9. The pharmaceutical composition of claim 6 , which is suitable for intravenous administration.
10. A solid pharmaceutical composition comprising a compound of the following formula, or a pharmaceutically acceptable salt, ester, or enantiomer thereof:
wherein:
R 7 is halogen or hydrogen;
R 9 is —NHC(═O)CH 2 R 9a ; and,
R 9a is acyl or heterocyclic; and,
wherein the compound is present in an amount effective to treat Gram-positive and/or Gram-negative bacterial infection in a range from about 0.01 to about 50 mg per kg per day.